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Summary
We demonstrate the metabolism of ergosterol by
cytochrome P450scc in either a reconstituted system
or isolated adrenal mitochondria. The major reaction
product was identified as 17,24-dihydroxyergoster-
ol. Purified P450scc also generated hydroxyergosterol
as a minor product, which is probably an intermediate
in the synthesis of 17,24-dihydroxyergosterol. In con-
trast to cholesterol and 7-dehydrocholesterol, cleav-
age of the ergosterol side chain was not observed.
NMR analysis clearly located one hydroxyl group to
C24, with evidence that the second hydroxyl group is
at C17. 17,24-Dihydroxyergosterol inhibited cell pro-
liferation of HaCaT keratinocytes and melanoma cells.
Thus, in comparison with cholesterol and 7-dehy-
drocholesterol, the 24-methyl group and the C22-C23
double bond of ergosterol prevent side chain cleav-
age by P450scc and change the enzyme’s hydrox-
ylase activity from C22 and C20, to C24 and C17, gen-
erating bioactive product.
Introduction
Cytochrome P450 side chain cleavage (P450scc), a
product of the CYP11A1 locus, is a mitochondrial en-*Correspondence: aslominski@utmem.eduzyme, the main function of which has been purported
to be the conversion of cholesterol to pregnenolone.
There is a single active site on the cytochrome where
successive hydroxylations of the cholesterol side chain
occur at positions 22 and 20, followed by cleavage of
the side chain to produce pregnenolone and isocapoic
aldehyde [1, 2]. Most recently, 7-dehydrocholesterol
has been uncovered as an additional substrate for
P450scc, yielding 7-dehydropregnenolone as a final
product [3, 4]. Aside from being a cholesterol precursor,
7-dehydrocholesterol is also a precursor for vitamin D3
through ultraviolet light B photolysis and temperature-
dependent intramolecular rearrangement [5, 6].
Ergosterol, a 5,7-diene sterol, is synthesized by fungi
and phytoplankton, but not in the animal kingdom [5].
Ergosterol serves as a major membrane sterol in fungi
[7], and can serve as the precursor for the synthesis
of vitamin D2 [5]. Ergosterol can act as a membrane
antioxidant [8] and a modifier of the effect of choles-
terol on human cell cycle progression [9]. Antitumor ef-
fects of ergosterol have been reported in cell culture
[10] and in vivo in rats [11]. Anticancerogenic and anti-
mutagenic properties of vitamin D2 (ergocalciferol) are
well recognized [5, 12] and, because of their lower tox-
icity (minimal hypercalcemic effect), hydroxylated forms
of vitamin D2 are considered as potential drugs for
treatment of cancer patients [5, 13], including those
with melanoma [14].
Ergosterol differs from 7-dehydrocholesterol in that
its side chain has a C24-methyl group and C22-C23
double bond. P450scc has been shown to cleave the side
chain of other plant sterols, including campesterol, which
also has a C24-methyl group [15]. Because 7-dehy-
drocholesterol also serves as a substrate for P450scc
[4] and has an identical ring system to ergosterol, we
tested whether cytochrome P450scc can metabolize
ergosterol.
Results
TLC and MS Characteristics of Ergosterol
Metabolites of Purified P450scc
Incubation of both human and bovine P450scc with er-
gosterol in a phospholipid-vesicle-reconstituted sys-
tem resulted in one major product and one minor prod-
uct being observed upon analysis by TLC (Figure 1A).
Both products were absent in the control incubations,
where P450scc was omitted. The products, eluted from
the TLC plate, had UV absorbance spectra identical to
that for ergosterol (not shown). A small spot corre-
sponding to pregnenolone (identity confirmed by mass
spectra, data not shown) was observed in the test sam-
ple for bovine P450scc (Figure 1A, lane 3). This is pro-
duced from a small quantity of cholesterol, which co-
purifies with P450scc extracted from adrenal glands
[16]. An electron impact mass spectrum of the major
product identified it as dihydroxyergosterol (Figure 1C).
It showed the molecular ion at m/z = 428, with fragment
ions at m/z = 410 (428 − H O) and m/z = 395 (410 −2
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932Figure 1. Analysis of Products of Ergosterol Metabolism in Vesicle-
Reconstituted P450scc
Ergosterol, at a molar ratio to phospholipid of 0.2, was incubated
for 1 hr with 0.75 M human P450scc (lane 2) or 2 M bovine
P450scc (lane 3) in a phospholipid vesicle-reconstituted system,
and the products analyzed by TLC (A). Lanes 1 and 4 are controls
with all components present except P450scc. Lane 5 contains er-
gosterol (ergo) and pregnenolone (preg) standards. The arrows la-
beling OH-ergo and DiOH-ergo indicate the positions of the re-
spective products of ergosterol metabolism, identified by EI mass
spectrometry as hydroxyergosterol (B) and dihydroxyergosterol (C).
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bCH3). In comparison, ergosterol has m/z = 396. These
results show that the major action of P450scc on ergos-
terol is to add two hydroxyl groups. The minor product
T
m
pas identified as hydroxyergosterol (Figure 1B). The
olecular ion was at m/z = 412 with fragment ions
/z = 394 (412 − H2O), m/z = 379 (394 − CH3), and
/z = 361 (379 − H2O). In contrast to cholesterol and
-dehydrocholesterol, the incubation of ergosterol with
450scc did not yield products indicative of cleavage
f the sterol side chain.
MR Analysis of Dihydroxyergosterol
he NMR analysis of TLC-purified dihydroxyergosterol
emonstrates that one OH group is located at C24 (Fig-
re 2). Although the presences of impurities in both the
ethyl region (0.5–1.5 ppm) and the expected hydroxyl
egion (3.0–4.5 ppm) prevents a definitive analysis, the
egions of the protons on the double bonds are rela-
ively clean. Both the chemical shifts and coupling pat-
erns of H6 and H7 are identical in ergosterol and this
etabolite. However, H22 and H23 in the side chain are
ownshifted from 5.18 ppm and 5.22 ppm to 5.35 ppm.
n addition, the correlation between H23 and H24
chemical shift of 1.86 ppm in ergosterol) is missing,
hereas that between H22 and H20 (chemical shift of
.04 ppm in ergosterol) is still present in this dihydroxyl
etabolite. This is a strong indication that H24 be-
omes hydroxylated in this metabolite. In addition, the
oublet of 28-methyl protons in ergosterol (0.92 ppm
or proton and 17.7 ppm for carbon) became a singlet
nd shifted downfield (1.3 ppm for proton and 24 ppm
or carbon). This again clearly defines the hydroxylation
t C24.
The presence of the impurities makes definitive as-
ignment of the second hydroxyl location very difficult.
lthough further HPLC purification (retention time [RT]
f 13.7) removed the impurities, the amount of purified
rgosterol metabolite was insufficient. Nevertheless,
he comparison of ergosterol and dihydroxyergosterol
eteronuclear single quantum correlation (HSQC) spec-
ra (Figure 2E) strongly indicates that the second hy-
roxyl group is located at C17. In Figure 2E, the two
ircled spots in the ergosterol HSQC spectrum (left)
orrespond to a correlation between 14-CH (1.89 ppm
or proton and 54.7 ppm for carbon) and 17-CH (1.27
pm for proton and 55.9 ppm for carbon). No such
pots are visible in those regions for the dihydroxyl me-
abolite (right spectrum). The correlation peak of 14-CH
n this metabolite shifted downfield to a new position
2.72 ppm for proton and 58.0 ppm for carbon), as indi-
ated in the circle in the right spectrum, whereas the
riginal 17-CH correlation disappeared. The shift of the
4-CH is caused by the formation of 17-OH in this me-
abolite. Hence, this dihydroxyl metabolite is most likely
7α,24-dihydroxylergosterol.
Based on the information presented in Figures 1 and
, we propose that P450scc transforms ergosterol to
7α,24-dihydroxylergosterol, with 24-hydroxyergos-
erol serving as an intermediate of the metabolism (Fig-
re 3).
he Rate of Ergosterol Metabolism
y Purified P450scc
o obtain an estimate of the initial rate of ergosterol
etabolism by P450scc, ergosterol, at a molar ratio to
hospholipid of 0.2, was incubated with P450scc for 5
Ergosterol Metabolism by P450scc
933Figure 2. NMR Analysis of the Hydroxylation
at Position 24-CH
Finger print regions in proton NMR spectra
of (A) ergosterol proton correlation spectros-
copy, (B) dihydroxyl metabolite, (C) ergos-
terol heteronuclear single quantum correla-
tion (HSQC) methyls, and (D) dihydroxyl
metabolite HSQC methyls. The corresponding
proton 1D NMR spectra are shown as pro-
jections. The formation of 24-OH is clearly
indicated by (1) the missing of H23-H24 cor-
relation in spectrum B with concurrent
downfield shift of H22 (5.18 ppm) and H23
(5.22 ppm) to 5.35 ppm; and (2) the transition
of 28 doublet methyl at 0.92 ppm in spectrum
C to a downfield singlet at 1.35 ppm in
spectrum D. (E) Part of proton-carbon HSQC
spectra of Ergosterol standard (left) and its
dihydroxyl metabolite (right). The two circled
spots in ergosterol HSQC spectrum (left)
correspond to correlation between H14 (1.89
ppm) and C14 (54.7 ppm), and H17 (1.27
ppm) and C17 (55.9 ppm). No such spots are
visible in those regions for ergosterol metab-
olite (right spectrum) due to 17-hydroxyla-
tion. The shift of HSQC correlation spot be-
tween H14 and C14 to the new position (2.72
ppm, 58.0 ppm) is caused by interaction of
14α hydrogen with the 17α-OH group.17.7 mol/min/mol P450scc [4].
Figure 3. Proposed Sequence for the
P450scc Catalyzed Transformation of Ergos-
terol with Structures of Expected Reaction
Products
of the substrate-free enzyme (Figure 4, spectrum 1),min at 35°C. The dihydroxyergosterol was extracted,
purified by TLC, and quantitated from its absorbance
at 281 nm. This gave a rate of metabolism of 0.7 mol
product/min/mol P450scc. Under similar conditions,
cholesterol was converted to pregnenolone at a rate ofThe Effect of Ergosterol and Dihydroxyergosterol
on the Spin State of Cytochrome P450scc
Cytochrome P450scc incorporated into phospholipid
vesicles prepared from dioleoyl phosphatidylcholine
and cardiolipin displays a typically low-spin spectrum
Chemistry & Biology
934Figure 4. The Effects of Ergosterol and Dihydroxyergosterol on the
Visible Absorbance of P450scc
P450scc was incorporated into phospholipid vesicles and spectra
recorded against a reference cuvette containing all components
except P450scc. (1) Vesicles containing no substrate; (2) vesicles
containing 0.1 mol cholesterol/mol phospholipid; (3) vesicles con-
taining both 0.1 mol cholesterol/mol phospholipid and 0.2 mol er-
gosterol/mol phospholipid; (4) vesicles containing both 0.1 mol
cholesterol/mol phospholipid and 0.004 mol dihydroxyergosterol/
mol phospholipid.
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clusion of ergosterol in the vesicles at a molar ratio to
phospholipid of 0.2 did not alter the spectrum (data not
shown). In contrast, the presence of cholesterol at a
molar ratio to phospholipid of 0.1 caused a transition
to the high-spin state, with maximum absorbance at
392 nm (Figure 4, spectrum 2). The magnitude of the
change in the spin state provides an index of substrate
binding, and we have previously used this to determine
the Kd for cholesterol and hydroxycholesterol reaction
intermediates, which bind competitively, in this system.
[18–20]. Ergosterol induced a shift toward the low-spin
state in the presence of cholesterol (Figure 4, spectrum
3). Thus, unlike cholesterol, ergosterol is a low-spin inducer
of P450scc. 17α,24-Dihydroxyergosterol also proved to be
a low-spin inducer (Figure 4, spectrum 4). This is similar
to 22R-hydroxycholesterol, but different from 20α,
22R-dihydroxycholesterol, which is a high-spin inducer
[18, 19].
The reversal of the high-spin shift induced by choles-
terol was used to determine the strength of ergosterol
binding to P450scc. In the presence of 0.05 mol choles-
terol/mol phospholipid, an apparent Kd for ergosterol
of 0.5 mol/mol phospholipid was obtained (Figure 5).
Extrapolation of the graph to infinite ergosterol con-
centration (zero on the X axis of Figure 5) reveals that,
as expected for competitive binding, ergosterol can
completely reverse the spin-state shift induced by
cholesterol. Analysis of the competitive binding (see
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mExperimental Procedures), using the Kd for cholesteroligure 5. Double Reciprocal Plot Showing Ergosterol Binding to
450scc in Phospholipid Vesicles Containing Cholesterol
esicles contained 0.05 mol cholesterol/mol phospholipid and er-
osterol at the indicated ratios. The open symbol on the Y axis
epresents the absorbance change expected for complete reversal
f cholesterol-induced high-spin state back to the substrate-free
ow-spin state. As, absorbance difference (416–392 nm) in the
resence of ergosterol; A0, absorbance difference (416–392 nm)
n the absence of ergosterol with 0.05 mol cholesterol/mol phos-
holipid present.etermined independently (0.033 mol cholesterol/mol
hospholipid), indicated 0.2 mol/mol phospholipid as
he true Kd for ergosterol. At a molar ratio to phospho-
ipid of only 0.004, dihydroxyergosterol caused a sub-
tantial shift toward the low-spin state in the presence
f 0.1 mol cholesterol/mol phospholipid. The limited
vailability of this product prevented us from determin-
ng its Kd, but from the concentration used and the
agnitude of the absorbance change, its Kd is at least
0 times lower than that for cholesterol.
rgosterol Metabolism by Adrenal Mitochondria
n agreement with the above results with purified
450scc, the RP-HPLC analysis of the reaction mixture
esulting from incubation of adrenal mitochondria with
rgosterol showed a single reaction product (metabo-
ite 1) at RT 14.2 min (ergosterol RT is 49.5.min), which
as absent in control samples (Figures 6A and 6B). The
bsorbance spectrum of this product was similar to
hat of ergosterol (Figures 6C and 6E) [4]. The mass
pectrum of metabolite 1 yielded a molecular ion char-
cteristic of the dihydroxyergosterol fragment with
M+H]+ at m/z = 411 (429 − H20), and a fragment ion at
/z = 393 (429 − 2H20) (Figure 6D). The mass spectrum
f ergosterol standard (RT = 49.5 min), in addition to
he expected ion m/z = 397 (minor product), also
ielded the same ions at m/z = 393 (major), indicating
hat ergosterol (theoretical m/z = 397) had undergone
esaturation during LC/MS. The ions [M+H]+ at m/z =
75 and at m/z = 425 obtained during MS analysis of
rgosterol (absent in the reaction product) represent
ethyl group (CH3) loss and methanol addition to de-saturated ergosterol, respectively (Figure 6F). Thus, as
Ergosterol Metabolism by P450scc
935Figure 6. RP-HPLC Identification of a Product of Ergosterol Metabolism by Adrenal Mitochondria
(A) Control (incubation without NADPH and isocitrate).
(B) Experimental incubation (with NADPH and isocitrate). The HPLC elution profiles were monitored by absorbance at 265 nm; the number 1
marks as the metabolite and 2 the ergosterol.
(C) UV spectra of reaction product at RT 14.2 min.
(D) Mass spectra of the reaction product at RT 14.2 min.
(E) UV spectra of ergosterol (RT 49.5 min).
(F) Mass spectra of ergosterol.for purified P450scc, the major product of ergosterol
metabolism by P450scc in adrenal mitochondria is di-
hydroxyergosterol.
Dihydroxyergosterol Inhibits Proliferation
of Human Skin Cells
Addition of 17α,24-dihydroxyergosterol (HPLC-purified)
to the culture media inhibited DNA synthesis in humanepidermal HaCaT keratinocytes, an effect that was ab-
sent in cultures treated with the ergosterol precursor
(Figure 7). The growth inhibitory effect for 17α,24-dihy-
droxyergosterol was observed at both high concentra-
tions (10−7 M and higher) and at low concentrations
(10−9 M or lower), with a reproducible lack of effect at
10−8 M (Figures 7A and 7B). Similar results were further
observed when 17α,24-dihydroxyergosterol was dis-
Chemistry & Biology
936Figure 7. 17α,24-Dihydroxyergosterol but not
Ergosterol Precursor Inhibits DNA Synthesis
in Human Skin Cells
Cultures of HaCaT keratinocytes were syn-
chronized and then incubated for 24 hr in
media containing serial dilutions of 17α,24-
dihydroxyergosterol dissolved in either EtOH
(A) or cyclodextrin (B), or serial dilutions of
ergosterol dissolved in EtOH (C). Data are
presented as mean ± SEM (n = 8), analyzed
with one-way analysis of variance with post
hoc Dunnett’s multiple comparison test (sig-
nificance at *p < 0.05). Each experiment was
performed twice. Insets in (A) and (B) show
that solvents at 0.2% concentration did not
modify DNA synthesis in control cultures,
and that the inhibitory effect for dihydroxyer-
gosterol at 10−6 M versus solvent is signifi-
cant (#p < 0.05).solved in either ethanol or cyclodextrin. The hiatus in
activity suggests that 17α,24-dihydroxyergosterol could
act both directly and indirectly through a more potent
metabolite, generated from 17α,24-dihydroxyergosterol
during the incubation of HaCaT keratinocytes. We have
also performed initial testing of melanoma cell line
SKMEL-188 and found that both 17α,24-dihydroxyer-
gosterol and ergosterol precursor inhibit DNA synthesis
in a dose-dependent manner (data not shown).
Discussion
We were able to demonstrate that P450scc in an in vitro
reconstituted system or in isolated mitochondria hy-
droxylates ergosterol to yield dihydroxyergosterol as
the major product. There appears to be no subsequent
metabolism of dihydroxyegrosterol by other steroido-
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benic enzymes present in adrenal mitochondria under
ur experimental conditions. Generation of a minor
roduct, hydroxyergosterol, was detected only by puri-
ied P450scc in a reconstituted system, indicating that
t represents an intermediate in the transformation to
he dihydroxyproduct (Figure 3). NMR analysis of dihy-
roxyergosterol demonstrated that one of the hydroxyl
roups is at C24. Additional NMR analysis indicated
hat the second hydroxyl group was located at C17. We
id not detect generation of 7-dehydropregnenolone
rom ergosterol in either the reconstituted system with
urified P450scc or with rat adrenal mitochondria. This
s in contrast to P450scc action on 7-dehydrocholesterol
n a reconstituted system or in adrenal mitochondria as-
ayed under identical conditions to those used for ergos-
erol, where 7-dehydropregnenolone is the sole detecta-
le product [4]. This suggests that structural features of
Ergosterol Metabolism by P450scc
937ergosterol side chain (e.g., the presence of C22-C23
double bond) prevent its cleavage by P450scc, leading
to a limited hydroxylation of the side chain at C24 and
C17 but not at C20 or C22, which is in contrast to cho-
lesterol and vitamin D3, in which P450scc hydroxylates
at both of these positions [3, 21]. Furthermore, the abil-
ity to cleave the side chain of 24α-methylcholesterol
(campesterol) by both human and bovine P450scc to
produce pregnenolone [21] excludes the 24-methyl
group as the major structural factor preventing the oxi-
dative cleavage of the side chain of ergosterol by
P450scc.
Binding of ergosterol and dihydroxyergosterol to
P450scc induced a shift toward the low-spin state of
the cytochrome. In contrast, cholesterol, 20α,22R-dihy-
droxycholesterol [18, 19], and 7-dehydrocholesterol
(unpublished data) are high-spin inducers. Thus, the
presence of the 24α-methyl group and the C22-C23
double bond of ergosterol alter the interaction with the
haem iron to produce the low-spin state. Ergosterol
binds to the active site of P450scc with an affinity only
one sixth of that for cholesterol, which may in part ex-
plain its lower hydroxylation rate compared with that
observed with an equivalent concentration of choles-
terol. Our preliminary studies show that dihydroxyer-
gosterol binding to P450scc is at least 30-fold tighter
than that of cholesterol. This higher affinity relative to
cholesterol is similar to the much tighter binding of
22R-hydroxycholesterol and 20α,22R-dihydroxycholes-
terol to P450scc, which helps ensure that the reaction
goes to completion without the accumulation of inter-
mediates [19, 22]. The tight binding of dihydroxyergos-
terol to P450scc likely results in competitive inhibition
during catalysis, as this final product saturates the
active site in preference to ergosterol. This might also
contribute to the relatively slow rate of metabolism of
ergosterol compared to cholesterol.
This surprising activity of mammalian P450scc to-
ward ergosterol raises questions about its biological
significance. Earlier studies reported that orally deliv-
ered ergosterol is absorbed by the alimentary tract
(2%–5% of total intake) and enters the systemic circu-
lation with highest accumulation and metabolism oc-
curring in the liver, lung, spleen, and adrenals [23, 24].
More recent studies have confirmed the intestinal ab-
sorption of ergosterol and its subsequent accumulation
and metabolism in the liver, intestine, skin, kidney, and
blood [25]. It is noteworthy that the ergosterol metabo-
lites detected in the skin were different from vitamin D2
[25]. In addition, cell culture studies clearly demon-
strate that ergosterol is efficiently taken up by human
cells (at 50% of the cholesterol uptake rate) [9]. There-
fore, it can be assumed that transformation of ergos-
terol to dihydroxyergosterol will probably occur in organs
expressing cytochrome P450scc, such as adrenals, go-
nads, placenta, brain [26], gastrointestinal tract [27],
kidney [28], and skin [4]. Accordingly, we have demon-
strated metabolism of ergosterol by mitochondria iso-
lated from adrenals (Figure 6). Moreover, ergosterol an-
titumor effects have been noted in cell cultures [10] and
in vivo [11].
Our cell culture studies demonstrate biological activ-
ity for 17α,24-dihydroxyergosterol, but not for ergos-
terol in terms of inhibition of proliferation of human im-mortalized epidermal keratinocytes. These results are
consistent with reports of minimal or nondetectable ef-
fects for unmodified ergosterol on human cell cycling
[9], whereas ergosterol metabolites have potent anti-
proliferative and anticancer effects on human and ani-
mal cells [10, 29–31]. It should also be noted that the
product of B ring breakage in ergosterol (vitamin D2),
promotes differentiation of keratinocytes in vivo, and
protects them from UVR-induced photodamage when
applied topically [12]. Concerning melanoma cells, we
found that both ergosterol precursor and dihydroxyer-
gosterol metabolite inhibit DNA sythesis, suggesting lo-
cal metabolism of ergosterol; of note is the observation
that melanoma cells do express P450scc [4].
In conclusion, we have demonstrated that ergosterol
serves as a substrate for mammalian P450scc generat-
ing bioactive 17α,24-dihydroxyergosterol. This reaction
proceeds in an in vitro reconstituted enzymatic system
and in adrenal mitochondria, but is restricted to hydrox-
ylations at positions C24 and C17 without detectable
side chain cleavage. Thus, of the two vitamin D precur-
sors that contain the 5,7-diene group in the B-ring, only
7-dehydrocholesterol (vitamin D3 precursor) can undergo
side chain cleavage by P450scc, producing 7-dehydro-
pregnenolone. Although the biological activity of the
7-dehydropregnenolone is unknown, 17α,24-dihydroxy-
ergosterol inhibits proliferation of skin cells in culture.
Significance
The present work uncovers a function for the key en-
zyme in steroidogenesis, cytochrome P450scc, well
known for its activity in cleaving the side chain of
cholesterol in the synthesis of steroid hormones. It
has been discovered that 7-dehydrocholesterol (pre-
cursor to vitamin D3) is an alternative substrate for
cytochrome P450scc and has its side chain cleaved
to produce 7-dehydropregnenolone (7-DHP). This
finding appears to define a metabolic pathway that
also provides an explanation for the increased con-
centrations of 7-DHP and its hydroxymetabolites in
Smith Lemli Opitz Syndrome (7-dehydrocholesterol
excess). Continuing our studies on vitamin D precur-
sors, we now demonstrate that the plant sterol and
precursor to vitamin D2, ergosterol, can also undergo
hydroxylation by mammalian cytochrome P450scc in
either a reconstituted system or isolated adrenal
mitochondria. The major reaction product was iden-
tified as 17,24-dihydroxyergosterol, with a minor
product, monohydroxyergosterol, which most likely
represents an intermediate in the synthesis of the
dihydroxyderivative. In contrast to the action of
P450scc on 7-dehydrocholesterol, cleavage of the
side chain of ergosterol was not observed. Thus, the
presence of the 24-methyl group and the C22-C23
double bond prevent side chain cleavage by P450scc,
and shift the enzyme hydroxylase activity from C22
and C20 to C24 and C17. 17,24-dihydroxyergosterol
has biological activity (inhibition of proliferation), as
demonstrated in human keratinocytes and melanoma
cell lines. Ergosterol itself has been previously re-
ported as being devoid of effects on human cell cy-
cling, whereas ergosterol metabolites have significant
Chemistry & Biology
938antiproliferative and anticancer properties. Dietary er-
gosterol is absorbed in the alimentary tract and also
taken up by mammalian cultured cells. It accumulates
in the adrenals and other organs, including skin,
but without conversion to vitamin D2. Thus, when
available to cells containing P450scc, ergosterol can
be metabolized in vivo to generate newer bioactive
products.
Experimental Procedures
Metabolism of Ergosterol by Reconstituted P450scc
P450scc and adrenodoxin reductase were purified from bovine
adrenal mitochondria [18, 32]. Adrenodoxin and human P450scc
were expressed in Escherichia coli (E. coli) and purified as pre-
viously reported [33]. Incubations of P450scc with ergosterol
(Sigma) were carried out in artificial phospholipid vesicles prepared
by sonication [34], as described for 7-dehydrocholesterol [4]. The
incubation mixture was comprised 510 M phospholipid vesicles
(dioleoyl phosphatidylcholine plus 15 mol% cardiolipin), with a sub-
strate to phospholipid molar ratio of 0.2, 50 M NADPH, 2 mM
glucose 6-phosphate, 2 U/ml glucose 6-phosphate dehydroge-
nase, 0.2 M adrenodoxin reductase, 10 M adrenodoxin, 2.0 M
cytochrome P450scc, and buffer, pH 7.4. The final volume was 2.0
ml for determining the rate of ergosterol metabolism and producing
product for mass spectra, and 50 ml for preparing products for
NMR. After incubation at 35°C for 1 hr (or other times as indicated
in the Results section), the mixture was extracted twice with 2 vol-
umes of methylene chloride, and the combined extracts dried
under nitrogen at 35°C. The extract was analyzed by thin-layer
chromatography on silica gel G with three developments in hex-
ane:ethyl acetate (3:1, v/v), as previously described [4]. Products in
selected lanes were visualized by charring. Corresponding prod-
ucts in other lanes were eluted from the silica gel as previously
described [4] and the amount of products determined from their
UV spectrum using an extinction coefficient of 9900 M−1 cm−1 at
281 nm, determined for the 5,7 diene structure of ergosterol.
Metabolism of Ergosterol by Adrenal Mitochondria
Adrenals were obtained from male Wistar rats aged 3 mo, termi-
nated under anesthesia. The animals were housed at the vivarium
of the Department of Biotesting of Bioorganic Chemistry Institute,
Minsk, Belarus). The experiments were approved by the Belarus
University Animal Care and Use Committee.
The adrenal mitochondrial fraction was prepared, and the
washed mitochondrial fraction resuspended in 0.25 M sucrose and
used for enzymatic reactions, as described previously [4]. Briefly,
isolated mitochondria were preincubated (10 min at 37°C) with the
sterols ergosterol or 7-dehydrocholesterol (20 M) dissolved in
45% 2-hydroxypropyl-cyclodextrin [4]. The reactions were started
by adding NADPH (0.5 mM) and isocitrate (5 mM), and stopped
after 90 min at 37°C, by adding ice-cold methylene chloride. The
mixtures were re-extracted two more times, dried, dissolved in
methanol, and analyzed on a HPLC mass spectrometer (LC-MS).
Measurement of Visible Absorbance Spectra
for P450scc and Ergosterol Binding
Vesicles were prepared from phosphatidylcholine and bovine heart
cardiolipin using a bath-type sonicator in buffer comprising 20 mM
Hepes (pH 7.4), 100 mM NaCl, 0.1 mM dithiothreitol, and 0.1 mM
EDTA, as described previously [34]. The cardiolipin content was
15 mol% of the total phospholipid. Ergosterol, dihydroxyergosterol
and/or cholesterol were included in the vesicles as required (see
Results). Purified P450scc (1.0 M) was incorporated into the vesi-
cles (400 M phospholipid) by incubation at room temperature for
30 min in a final volume of 0.7 ml [34]. Spectra were recorded be-
tween 350 and 500 nm against a reference cuvette containing all
components except P450scc. The Kd for cholesterol was deter-
mined by titrating the absorbance change between 316 and 412
nm with cholesterol, as previously described [19]. The Kd for ergos-
terol was determined by its ability to reverse the absorbance
change induced by cholesterol using competitive binding analysis
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hith the equation: Kd = Kd, app/(1 + [I]/KI]), where Kd, app
s the apparent Kd for ergosterol in the presence of cholesterol, I
s the cholesterol concentration, and KI is the Kd for cholesterol.
his method has been used previously to determine Kd values for
0α-hydroxycholesterol and 22R-hydroxycholesterol binding to
450scc [19].
ass Spectrometry
roducts of ergosterol metabolism by purified P450scc were eluted
rom TLC plates, dissolved in ethanol, and electron impact (EI)
ass spectra were recorded with a Micromass VG Autospec mass
pectrometer operating at 70 eV, with scanning from 800 to 50 at 1
ec/decade.
The products of incubation of ergosterol with mitochondria were
nalyzed on an LCMS-QP8000α (Shimadzu, Kyoto, Japan) equip-
ed with a Restec Allure C18 column (150 × 4.6 mm; 5 m particle
ize; and 60 Å pore size), UV/VIS photodiode array detector (SPD-
10Avp), and quadrupole mass spectrometer. The LC-MS work-
tation Class-8000 software was used for system control and data
cquisition (Shimadzu, Japan). Elution was carried out at 40°C with
flow rate of 0.75 ml/min. The mobile phases consisted of 85%
ethanol and 0.1% acetic acid from 0 to 25 min, followed by a
inear gradient to 100% methanol and 0.1% acetic acid from 25 to
5 min; and 100% methanol and 0.1% acetic acid from 35 to 55
in. The MS operated in atmospheric pressure chemical ionization
ositive-ion mode, and nitrogen was used as the nebulizing gas.
he MS parameters were as follows: the nebulizer gas flow rate
as 2.5 l/min, probe high voltage was 3.5 kV, probe temperature
as 300°C, and the curved desolvation line heater temperature was
50°C. Analyses were carried out in scan mode from m/z 320 to
50 or, in SIM mode, at the expected m/z of the standards.
uclear Magnetic Resonance
LC-purified (see above) dihydroxyergosterol (the mass of the
ompound was confirmed by MS) was dissolved in CDCl3 (Cam-
ridge Isotope Laboratories, Inc., Andover, MA). and NMR spectra
ere acquired using a Varian Inova-500 M NMR equipped with a
mm gHX Nanoprobe (Varian NMR, Inc., Palo Alto, CA). The total
olume in the NMR rotor was 40 l, and all spectra were acquired
t a temperature of 294 K, with a spinning rate of 2500 Hz. Proton
D NMR, proton correlation spectroscopy and proton-carbon cor-
elation spectroscopy (HSQC) were acquired and processed with
tandard parameters. Possible positions of the hydroxyl groups in
he metabolite were analyzed by comparing the acquired spectra
ith those of parent ergosterol.
Because of the impurities in TLC-purified dihydroxyergosterol
impairing assignment of one of the hydroxyl groups; see below), it
as purified by RP-HPLC through Allure C18 column (150 × 4.6
m; 3 m particle size; Restek Corporation, Bellefonte, CA), fol-
owing the procedure described for LC-MS, and then analyzed by
MR (see above).
ell Proliferation Assays
he assays followed methodology routinely used in our laboratory
35]. Briefly, HaCaT keratinocytes and SKMEL-188 melanoma cells
ere respectively cultured in DMEM or Ham’s F10 medium, supple-
ented with 5% FBS and 1% antibiotic solution (GIBCO). To mea-
ure DNA synthesis, the cells were seeded into 96-well plates
5,000 per well). After 6 hr, the medium was replaced with serum-
ree Ham’s F10 medium to synchronize the cells in cell cycle [36].
fter 12 hr, the medium was changed to Ham’s F10, containing 5%
BS plus graded dilutions of dihydroxyergosterol. In control cells,
ihydroergosterol was replaced with solvent ethanol (EtOH) or α-cyclo-
extrin (0.2% solvent corresponding to the same concentration as
n dihydroxyergosterol at 10−6 M). Twelve hours later, it was re-
laced with fresh medium containing serial dilutions of dihydroxy-
rgosterol and [3H]-thymidine (1 Ci/ml) for 12 hr incubation. The
edia were then discarded, cells detached with trypsin, harvested
n fiber glass filter, and radioactivity (proportional to methyl-
3H]thymidine incorporated into DNA) counted with a Packard di-
ect β counter (Packard, Meriden, CA).
Data were analyzed with one-way analysis of variance with post
oc Dunnett’s Multiple Comparison Test using Prism 4.00 (Graph-
Ergosterol Metabolism by P450scc
939Pad Software, San Diego, CA). Data are presented as mean ± SEM
(n = 8).
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